JPMorgan initiated coverage of Upstream Bio (UPB) with an Overweight rating and $38 price target Upsteam’s lead asset is verekitug, a recombinant human IgG1 monoclonal antibody that binds the thymic stromal lymphopoietin receptor to treat severe asthma, chronic rhinosinusinitis with nasal polyps and COPD, the analyst tells investors in a research note. The firm sees verekitug as the sole driver for shares over the mid to long term as the clinical profile matures.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UPB:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue